Biocept Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Biocept (BIOC) Tops Q1 EPS by 19c
May 12, 2021 4:24 PM EDTBiocept (NASDAQ: BIOC) reported Q1 EPS of $0.19, $0.19 better than the analyst estimate of $0.00. Revenue for the quarter came in at $17.8 million versus the consensus estimate of $13.67 million.
We are reporting profitability for the second consecutive quarter on revenues of $17.8 million, as our dedicated Biocept team continued to serve our community with COVID-19 RT-PCR testing featuring exceptional customer service and rapid turnaround times, said Michael Nall, Biocepts President and CEO. These outstanding financial results support further advancements with our core oncology business and more specifically our focus on neuro-oncology as we build for a strong... More



